
Rochelle Walensky
Harvard Medical School
Associate Professor of Medicine
http://www.harvardscience.harvard.edu/directory/researchers/rochelle-p-walensky
Rochelle Walensky, MD, MPH is Associate Professor of Medicine at Harvard Medical School, and a practicing Infectious Disease physician at Brigham and Women’s and Massachusetts General Hospitals. Dr. Walensky has been a member of the CEPAC team since 1998. Her research interests have focused on HIV/AIDS policy and cost-effective strategies of HIV care in the US and in resource-limited settings. She is nationally recognized for motivating US policy toward the promotion of routine HIV screening. She is the 2008 winner of the Emerging Leader in HIV Research sponsored by the HIV Medical Association and the Infectious Disease Society of America. Dr. Walensky received her BA from Washington University in St. Louis (1991), her MD from the Johns Hopkins School of Medicine (1995), and her MPH from the Harvard School of Public Health (2001). She trained in Internal Medicine and the Johns Hopkins Hospital (1995-1998) and in Infectious Disease at the MGH/BWH combined fellowship program (1998-2001).
Projecting the benefits of antiretroviral therapy for HIV prevention: the impact of population mobility and linkage to care 
Andrews JR, Wood R, Bekker LG, Middelkoop K, Walensky RP
J Infect Dis. 2012 Jul. 206 (4): 543-51
The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis 
Andrews JR, Lawn SD, Rusu C, Wood R, Noubary F, Bender MA, Horsburgh CR, Losina E, Freedberg KA, Walensky RP
AIDS 2012 Apr. 26 (8): 987-95
Research areas: tuberculosis
Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis 
Andrews JR, Noubary F, Walensky RP, Cerda R, Losina E, Horsburgh C
Clin Infect Dis 2012 Feb. 54 (6): 784-91
Research areas: tuberculosis
Apparent declining efficacy in randomized trials: examples of the RV144 HIV vaccine and CAPRISA 004 microbicide trials 
O'Hagan J, Hernán MA, Walensky R, Lipsitch M
AIDS 2011 Dec. 26 (2): 123-6
First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial 
Ciaranello AL, Lockman S, Freedberg KA, Hughes M, Chu J, Currier J, Wood R, Holmes CB, Pillay S, Conradie F, McIntyre J, Losina E, Walensky RP, CEPAC-International, OCTANE I
AIDS 2011 Jan. 25 (4): 479-92
Cost-effectiveness of HIV testing referral strategies among tuberculosis patients in India 
Uhler LM, Kumarasamy N, Mayer KH, Saxena A, Losina E, Muniyandi M, Stoler AW, Lu Z, Walensky RP, Flanigan TP, Bender MA, Freedberg KA, Swaminathan S, CEPAC I
PLoS One 2010 Aug. 5 (9): e12747
Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC 
Walensky RP, Paltiel AD, Losina E, Morris BL, Scott CA, Rhode ER, Seage GR, Freedberg KA, CEPAC I
Clin Infect Dis 2010 Jul. 51 (4): 392-400
Does modality of survey administration impact data quality: audio computer assisted self interview (ACASI) versus self-administered pen and paper? 
Reichmann WM, Losina E, Seage GR, Arbelaez C, Safren SA, Katz JN, Hetland A, Walensky RP
PLoS One 2009 Dec. 5 (1): e8728
Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal 
Losina E, Touré H, Uhler LM, Anglaret X, Paltiel AD, Balestre E, Walensky RP, Messou E, Weinstein MC, Dabis F, Freedberg K, CEPAC I
PLoS Med 2009 Sep. 6 (10): e1000173
When to start antiretroviral therapy in resource-limited settings 
Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, Martinson NA, Paltiel AD, Anglaret X, Weinstein MC, Losina E, CEPAC
Ann Intern Med 2009 Jul. 151 (3): 157-66
HIV pre-exposure prophylaxis (PrEP) in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness 
Paltiel AD, Freedberg KA, Scott C, Schackman BR, Losina E, Wang B, Seage G, Sloan C, Sax PE, Walensky RP
Clin Infect Dis 2009 Feb. 48 (6): 806–815
Antiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity 
Ciaranello AL, Seage G, Freedberg KA, Weinstein MC, Lockman S, Walensky RP
AIDS 2008 Oct. 22 (17): 2359-69
Scaling up antiretroviral therapy in South Africa: the impact of speed on survival 
Walensky RP, Wood R, Weinstein MC, Martinson NA, Losina E, Fofana MO, Goldie SJ, Divi N, Yazdanpanah Y, Wang B, Paltiel AD, Freedberg KA, CEPAC-International I
J Infect Dis. 2008 Apr. 197 (9): 1324-32
The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men 
McCormick AW, Walensky R, Lipsitch M, Losina E, Hsu H, Weinstein MC, Paltiel AD, Freedberg KA, Seage G
Clinical Infectious Diseases 2007 Mar. 44 (8): 1115-1122
Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs 
Paltiel AD, Walensky RP, Schackman BR, Seage G, Weinstein MC, Freedberg KA
Ann Int Med 2006 Nov. 145 (11): 797-806
The lifetime cost of HIV care in the United States in the era of highly active antiretroviral therapy 
Schackman BR, Gebo KA, Walensky RA, Losina E, Muccio T, Sax PE, Weinstein MC, Seage G, Moore RD, Freedberg KA
Med Care 2006 Oct. 44 (11): 990-997
Impact of opportunistic diseases on chronic mortality in HIV-infected adults in Côte d'Ivoire 
Losina E, Anglaret X, Yazdanpanah Y, Wang B, Toure S, Seage G, N'Dri-Yoman T, Walensky RP, Dakoury-Dogbo N, Goldie SJ, Messou E, Weinstein MC, Deuffic-Burban S, Salamon R, Freedberg KA
S Afr Med J 2006 May. 96 (6): 526-9
Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-TB co-infected populations 
Cohen T, Lipsitch M, Walensky R, Murray M...
Proceedings of the National Academy of Sciences of the United States of America 2006 Apr. 103 (18): 7042-7047
Research areas: tuberculosis
Expanded screening for HIV disease in the United States: clinical impact and cost-effectiveness 
Paltiel AD, Weinstein MC, Kimmel AD, Seage GR, Losina E, Zhang H, Freedberg KA, Walensky RP
New Eng J Med 2005 Jun. 352 586-95
Routine HIV testing: an economic evaluation of current guidelines 
Walensky RP, Weinstein MC, Kimmel AD, Seage G, Losina E, Sax PE, Zhang H, Smith HE, Freedberg KA, Paltiel AD
Am J Med 2005 Feb. 118 (3): 292-300
A therapeutic HIV vaccine: how good is good enough? 
Walensky RP, Paltiel AD, Goldie SJ, Gandhi RT, Weinstein MC, Seage G, Smith HE, Zhang H, Freedberg KA
Vaccine 2004 Aug. 22 (29-30): 4044-53
Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection 
Goldie SJ, Paltiel AD, Weinstein MC, Losina E, Seage G, Kimmel AD, Walensky RP, Sax PE, Freedberg KA
Am J Med 2003 Nov. 115 (8): 632-41
Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy 
Walensky RP, Goldie SJ, Sax PE, Weinstein MC, Paltiel AD, Kimmel AD, Seage G, Losina E, Zhang H, Islam R, Freedberg KA
J Acquir Immune Defic Syndr 2002 Aug. 31 (1): 27-37